Application of channel blocker in preparation of drugs for treating and / or preventing liver fibrosis
Patent Information
- Application Number
- JP2023195463
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-22
- Filing Date
- 2023-11-16
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2043-11-16
Smart Images

Figure 2024167865000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the technical field of biomedicine, in particular to the use of channel blockers in the manufacture of a medicament for the treatment and / or prevention of liver fibrosis. [Background technology]
[0002] Chronic liver disease is a global challenge that seriously affects people's quality of life. The incidence and mortality of liver cirrhosis and primary hepatocellular carcinoma are both very high. Liver fibrosis is the pathological basis of these chronic liver diseases and also the pathogenic mechanism of liver cirrhosis and liver cancer. Numerous studies have confirmed that liver fibrosis can be caused by various causes, including alcohol, viruses, medicines, toxins, immune and metabolic disorders, etc. Continuous stimulation of these substances can cause serious liver damage. The development mechanism of liver fibrosis is also related to various factors, and the activation of hepatic stellate cells (HSCs) is one of the important factors in its pathogenesis mechanism. Influenced by various factors, hepatic parenchymal cells cause persistent inflammatory necrosis, which activates HSCs and further proliferates in large quantities, while releasing large amounts of extracellular matrix (ECM). These substances promote the massive proliferation of fibrous connective tissue, eventually forming fibrous scars, which further damages the structure and function of the liver, and ultimately causes liver fibrosis. Therefore, inhibition of activated HSCs has important implications in the treatment of liver fibrosis.
[0003] At present, the treatment of liver fibrosis is still in the budding stage, and some effective medicines have been discovered, but most of them are pathological treatments, and have shortcomings such as long treatment period, low therapeutic effect, and many side effects, which have perplexed the global medical community. Early detection of factors that cause liver fibrosis and timely suppress the progression to chronic liver disease are currently one of the major tasks. Therefore, studying the pathogenesis mechanism of liver fibrosis, searching for new therapeutic targets, and developing medicines that can effectively treat liver fibrosis and are safe, reliable, and inexpensive are of great social and medical significance. Summary of the Invention
[0004] The object of the present invention is to solve the problems existing in the prior art mentioned above by providing the use of a channel blocker in the manufacture of a medicament for the treatment and / or prevention of liver fibrosis.
[0005] In order to achieve the above object, the present invention provides the following technical means. The present invention provides the use of a channel blocker in the manufacture of a medicament for the treatment and / or prevention of liver fibrosis.
[0006] Preferably, the channel blocker is a sodium channel blocker.
[0007] Preferably, the sodium channel blocker comprises phenytoin sodium.
[0008] Preferably, said liver fibrosis comprises carbon tetrachloride induced liver fibrosis.
[0009] Preferably, the pharmaceutical product further comprises a pharma- ceutically acceptable auxiliary material.
[0010] Preferably, the pharmaceutical formulation is in any medically acceptable dosage form.
[0011] Preferably, the pharmaceutical dosage form includes powder, injection, capsule, tablet, oral liquid.
[0012] The present invention further provides the use of phenytoin sodium in the manufacture of a medicament for inhibiting autophagy in liver tissue.
[0013] The present invention further provides the use of phenytoin sodium in the manufacture of a medicament for inhibiting hepatic stellate cell proliferation.
[0014] The invention further provides the use of phenytoin sodium in the manufacture of a medicament for downregulating hepatocyte α-SMA.
[0015] The present invention further provides the use of phenytoin sodium in the manufacture of a medicament for downregulating hepatocyte LC3.
[0016] The present invention provides the use of phenytoin sodium in the manufacture of a medicament for upregulating hepatocyte P62.
[0017] The present invention discloses the following technical effects. The present invention proves that phenytoin sodium can improve liver fibrosis by controlling autophagy at the cellular level, thereby influencing the activation of hepatic stellate cells. Furthermore, the present invention further establishes a disease model to verify the therapeutic effect of phenytoin sodium on liver fibrosis at the animal level, and proves that it can be used to manufacture medicines for the treatment and / or prevention of liver fibrosis. [Brief description of the drawings]
[0018] [Figure 1] FIG. 1 shows a mouse liver fibrosis model and the effects on mouse liver function after phenytoin sodium treatment (A: general morphology of mouse liver in each group; B: ALT statistics of mice in each experimental group; C: AST statistics of mice in each experimental group). [Diagram 2]Liver fibrosis in mice of each group was observed by staining with HE, Masson, and picrosirius red (A: HE staining, B: Masson staining, C: Tensidoc staining). [Diagram 3] The expression status of α-SMA in each experimental group detected by immunohistochemistry (A) and a statistical chart (B). [Figure 4] Expression of hepatic fibrosis indicators and autologous indicators in the liver tissue of the experimental mice of each group detected by Western blot, and statistical diagrams (A, D: Expression status and statistical diagram of α-SMA in the liver tissue of the experimental mice of each group; B, E: Expression status and statistical diagram of LC3 in the liver tissue of the experimental mice of each group; C, F: Expression status and statistical diagram of P62 in the liver tissue of the experimental mice of each group). [Diagram 5] FIG. 5 shows the effect of phenytoin sodium on hepatic stellate cell (HSC) proliferation detected by CCK8 method. [Figure 6] 1 shows the effect of TGF-β1 on HSCs proliferation by CCK8 method and the effect of phenytoin sodium on TGF-β1-induced HSCs proliferation. [Figure 7] Expression and statistical diagrams of α-SMA, LC3, and P62 in cells of different experimental groups detected by Western blot (A, D: Expression and statistical diagrams of α-SMA in HSC cells of each experimental group; B, E: Expression and statistical diagrams of LC3 in HSCs of each experimental group; C, F: Expression and statistical diagrams of P62 in HSCs of each experimental group). [Figure 8] FIG. 1 shows the expression and statistical diagrams of α-SMA and autophagy-related proteins LC3 and P62 in HSCs after the addition of rapamycin, as detected by Western blot experimental technique (wherein A and D are the expression and statistical diagrams of α-SMA in HSCs; B and E are the expression and statistical diagrams of LC3 in HSCs; C and F are the expression and statistical diagrams of P62 in HSCs). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] Although various exemplary embodiments of the present invention will be described in detail, it should be understood that the following detailed description is not intended to limit the invention, but rather to describe in more detail certain aspects, features and embodiments of the present invention.
[0020] Example 1: Animal studies with phenytoin sodium 1. Establishment and treatment of a mouse model of liver fibrosis 1.1 Experimental steps and methods (1) Experimental groups: model group, treatment group, normal group and drug group (15 healthy male C57 mice (purchased from Chongqing Tengxin Biotechnology Co., Ltd.) in each group, a total of 60 mice)
[0021] (2) Establishment of a mouse model of hepatic fibrosis: Establishment of the model was started when male C57 mice, which had been raised normally, reached a body weight of 20 g. Mice in the model and treatment groups were given 20% CCl 4 Olive oil solution (5 mL / kg) was administered intragastrically twice a week for a total of 8 weeks. All mice were kept normally.
[0022] (3) Prevention and treatment with phenytoin sodium: After the second week of model establishment, the treatment group and drug group were intraperitoneally injected with phenytoin sodium (1 mM; 10 mL / kg) once a day, and the injections were stopped after the model was successfully established in the model group. The mice in the normal group and model group were intraperitoneally injected with the same volume of saline.
[0023] (4) Sample collection: After successful modeling, mice from each group were dissected, and eyeball blood was collected to measure serological indicators. The livers were harvested to observe the appearance of the liver with the naked eye, photographed and recorded, and two samples were taken from the liver tissue, fixed in formalin, embedded in paraffin, and finally paraffin sections were prepared for HE, picric acid picrosirius red, Masson staining and immunohistochemistry, and the remaining tissues were frozen and stored at -80℃ for further use.
[0024] (5) HE staining of liver sections: Mouse liver tissue was fixed with formalin, embedded in paraffin, and paraffin sections were prepared using adhesive slides. The sections were placed in a 70°C incubator and baked for 1-2 hours, and then deparaffinized in the usual manner (soaked in xylene solution I for 10 minutes, xylene solution II for 10 minutes, absolute ethanol for 5 minutes, 95% ethanol for 5 minutes, 80% ethanol for 5 minutes, 75% ethanol for 5 minutes, and 50% ethanol for 5 minutes, and finally washed three times with PBS buffer. (10 minutes each time)), then stained (stained with hematoxylin for 5 minutes, differentiated with hydrochloric acid ethanol for 10 seconds, then washed with tap water for 10 minutes until the blue color was restored, then stained with 0.5% eosin solution for 3 minutes, and washed with running water for 5 minutes), finally, the samples were dehydrated (50% ethanol for 1 minute, 75% ethanol for 1 minute, 80% ethanol for 1 minute, 95% ethanol for 1 minute, and absolute ethanol for 1 minute), the slides were sealed with neutral rubber, and finally observed under a microscope, photographed, and stored.
[0025] (6) Masson trichrome staining of liver sections: Paraffin sections of liver were deparaffinized, and the prepared Weigert iron hematoxylin stain was dropped onto the tissue for 5-10 minutes, then differentiated in acidic ethanol differentiation solution for 5-15 seconds, washed with water, further blued in Masson blueing solution for 3-5 minutes, washed with distilled water for 1 minute, stained with Ponceau red magenta staining solution for 5-10 minutes, and then prepared a weak acid working solution using distilled water and weak acid solution in a 2:1 ratio, and washed with the weak acid working solution for 1 minute. They were washed in phosphomolybdic acid solution for 1-2 min, washed in weak acid working solution for 1 min, stained in aniline blue staining solution for 1-2 min, washed in weak acid working solution for 1 min, rapidly dehydrated in 95% ethanol, dehydrated three times in absolute ethanol (5-10 s each time), cleared three times in xylene (1-2 min each time), mounted in neutral rubber, and photographed under a microscope for recording.
[0026] (7) Picric acid picrosirius red staining of liver sections: In a clean environment, the liver paraffin sections were deparaffinized, then immersed in hematoxylin solution for 2 minutes, washed with tap water for 10 minutes, differentiated in 1% hydrochloric acid ethanol for 5 seconds, washed with tap water for 10 minutes, immersed in picric acid picrosirius red staining solution for 20 minutes, washed with tap water for 5 minutes, dehydrated, mounted, and photographed under a microscope for recording.
[0027] (8) Immunohistochemistry: Paraffin sections of the liver were deparaffinized and then washed with 3% H. 2 O 2 The specimens were immersed in the solution and incubated for 5-10 minutes, then washed with distilled water, washed with PBS for 5 minutes, and repeated twice. The antigens were restored with sodium citrate and washed with PBS for 5 minutes. α-SMA antibody was added and stirred overnight at 4°C. After reheating for 30 minutes, the specimens were washed with PBS, and repeated three times (5 minutes each time), enzyme-labeled monoclonal antibody mouse rabbit IgG was added and incubated at 37°C for 30 minutes, and then washed with PBS. The specimens were developed with a color developer for 1 minute (DAB), then thoroughly washed with water, stained again, dehydrated, cleared, and finally mounted, photographed under a microscope, and analyzed.
[0028] (9) Protein immunoblotting experiment (Western-Blot): 1) Extraction of protein stock solution Extraction of cell protein: Take out the cells from which protein needs to be extracted from the incubator, wash them twice with the prepared PBS solution, place them on a clean filter paper, dry the remaining PBS, then add a specific amount of RIPA protein dissolution solution according to the growth status of the cells, and leave it for about 30 minutes to decompose the protein. Next, scrape off the decomposed protein stock solution with a cell scraper and put it into the prepared EP tube, then put it into a high-speed centrifuge and centrifuge it at 12000 rpm for 30 minutes at 4℃. After the centrifugation is completed, take the supernatant and perform the following protein quantification.
[0029] 2) Protein quantification An EP tube was taken, and 25 μL of standard protein BSA and 75 μL of PBS were added thereto to prepare a 0.5 mg / mL BSA standard protein solution. Next, a 96-well plate was taken, and a specific amount of PBS and BSA was added to each well to create a standard curve, and then the protein stock solution was diluted, and 87 μL of PBS solution was added to the EP tube, and then 3 μL of the centrifuged protein stock solution (30-fold dilution) was added. Next, a BCA working solution was prepared with a concentration ratio of 50:1 using solution A and solution B, and 200 μL was added to each well of the 96-well plate, and the mixture was left in an incubator for 30 minutes, and the temperature was set to 37 ° C. Finally, the concentration of the protein stock solution was detected with a microplate reader, and the concentration ratio was calculated, and then the RIPA protease dissolution solution was added to the protein stock solution to adjust the protein stock solution to the same concentration, and then an equal amount of 5 × loading buffer was added to each EP tube, boiled in boiling water for 5 minutes, cooled, and then placed in a refrigerator at -20 ° C.
[0030] 3) Western Blot Experimental Procedure a. Preparation of electrophoresis gel b. Loading and gel running: The prepared electrophoresis gel was placed in the electrophoresis tank, electrophoresis solution was added, the loading comb was pulled out, the protein marker was taken from the refrigerator, 4 μL was taken and added to the hole, the target protein was added to the remaining hole, the cover was put on, the voltage was adjusted to 80 V, and the gel running was started. When the protein marker band was separated into multiple bands, the voltage was adjusted to 120 V, and the electrophoresis was terminated when the desired position of the target protein appeared. c. Transfer: Take out the PVDF membrane and cut it to the required size, then soak it in methanol solution for 5-10 minutes. Take out the gel from the electrophoresis tank, cut out the required gel according to the marker band according to the molecular weight of the target protein, cover the marked PVDF membrane with the corresponding gel, place filter paper and sponge in order, then place it in the electric transfer tank, add electric transfer solution, adjust the voltage to 90V, and set the electric transfer time according to the molecular weight of the target protein. d. Blocking: After completion of the electric transfer, the PVDF membrane was taken out and washed with TBST for 5 minutes. Next, the TBST was discarded, and the prepared 5% protein blocking solution was added and the membrane was rocked on a rocking shaker for 1.5 hours. e. Primary antibody incubation: The blocked PVDF membrane was washed with TBST three times (10 min each time), and then transferred to the prepared primary antibody and allowed to stand overnight. f. Secondary antibody incubation: Remove the PVDF membrane from the primary antibody, wash it with TBST three times (10 minutes each time), then place it in the secondary antibody with rocking for 2 hours, remove the PVDF membrane, and wash it again with TBST three times (10 minutes each time). g. Color development: The developer was dropped onto the PVDF membrane and exposed to light. h. Result analysis: Band gray value analysis statistics were performed on the exposure results using the software Image J.
[0031] 1.2.Experimental Results (1) During the modeling process, the mental state of the mice in the model group gradually deteriorated, their activity decreased, their food intake and water intake decreased, and their CCl 4 The results indicate that the presence of β-lactamase leads to liver damage, thereby affecting the healthy growth of mice. Compared with the model group, the treatment group had less smooth fur but significantly increased activity, while the normal and drug groups had smooth fur, were active, and had normal food and water intake.
[0032] (2) After successful modeling, the mice were dissected and the appearance of the liver was observed with the naked eye, photographed and recorded. As shown in Figure 1A, the differences and changes in the appearance of the mouse livers in each group were clearly observed. The normal group and the drug group had no obvious differences in the mouse livers, and the liver quality was soft and the surface was smooth. The liver quality of the mice in the model group was hard, the glossiness was low, the surface was rough, and the entire liver was yellowed. The liver quality of the mice in the treatment group was softer than that of the model group, but harder and less glossy than that of the normal group.
[0033] (3) Detection of liver function (ALT, AST): Eyeball blood was collected from each group of mice, centrifuged to collect serum, and sent to the hospital laboratory to measure alanine aminotransferase (ALT) and aspartate aminotransferase (AST) using a device. As shown in Figure 1B and Figure 1C, the aminotransferase in the model group was higher than that in the normal group, indicating that the liver fibrosis model was successfully established. The aminotransferase in the treatment group was lower than that in the model group, and the difference was statistically significant (p<0.05), indicating that phenytoin sodium can improve liver fibrosis. There was no obvious difference in aminotransferase between the drug group and the normal group, suggesting that the drug is not damaging to the liver.
[0034] (4) HE, Masson trichrome, picrosirius red staining of liver sections: In the normal and drug groups, the hepatic lobules of mouse liver tissue were intact and the structure was normal. In the model group, a large amount of collagen deposition was observed around the portal area of mouse liver tissue, and the formation of fibrous spaces was observed between the portal area and the central vein, and the structure of the hepatic lobules was disrupted, whereas in the treatment group, the degree of hepatic fibrosis was reduced compared to the model group (Figure 2), indicating that phenytoin sodium can reduce the collagen content in mouse liver and reduce the degree of hepatic fibrosis.
[0035] (5) Detection of α-SMA expression in tissues of different experimental groups by immunohistochemistry using liver sections: As shown in Figure 3, the normal group and drug group only had a small amount of positive expression at the periphery of the hepatic portal vein and a small amount of central vein, while the model group showed a large amount of positive expression around the portal vein area and intralobular inflammatory necrotic areas and within the hepatic sinusoidal wall. The treatment group showed a decreased amount of positive expression compared to the model group, and the results were statistically significant (p<0.05).
[0036] (6) Detection of the expression of α-SMA, LC3, and P62 in tissues of different experimental groups by Western blot: Compared with the normal group, the model group had increased expression of liver fibrosis indicator α-SMA and autophagy-related indicator LC3 in liver tissue, and decreased expression of P62, while the treatment group had decreased expression of liver fibrosis indicator α-SMA and autophagy-related indicator LC3, and increased expression of P62, and the difference was statistically significant (p<0.05) (Figure 4). The above results indicate that phenytoin sodium can improve liver fibrosis lesions and may be related to the autophagy pathway.
[0037] Example 2: Cellular experiments with phenytoin sodium 1. Effect of phenytoin sodium on liver fibrosis at the cellular level 1.1.Experimental Method (1)Cell culture 1) Cell resuscitation After 30 minutes of irradiation with a clean bench ultraviolet lamp, turn on the white light and circulating airflow, take a centrifuge tube and add 3 mL of culture medium thereto, immediately take out the frozen cells from the -80°C refrigerator and put them in a 37°C constant temperature water bath to thaw, then aspirate the cells in the clean bench and put them into the prepared centrifuge tube, seal them and put them in a centrifuge to centrifuge for 5 minutes (rotation speed: 1000 rpm), then prepare a culture flask, mark the cell name and date, discard the supernatant after centrifugation is completed, add new culture medium and mix uniformly, finally put the uniformly mixed cells into the marked culture flask, spray the flask with 75% alcohol, and then put it into a constant temperature incubator for culture.
[0038] 2) Cell passage: DMEM complete medium, trypsin and sterile PBS were placed in a clean bench, reheated for 30 minutes, white light and circulating airflow were turned on, alcohol lamp was lit, the cells that needed to be passaged were taken out of the incubator, the medium was discarded, sterile PBS was added to wash twice, then the PBS was discarded, 1mL of trypsin was added to the flask, and it was placed under a microscope to observe, when the interval between the cells became large and the cells became round, the trypsin was immediately discarded, 3-5mL of medium was added to the flask to stop digestion, then the cells were pipetted with a pipette and evenly distributed into a new culture flask, and the flask was marked with the cell name, passage number and passage time. Finally, the flask was sprayed with 75% alcohol and then placed in a constant temperature incubator for continued culture.
[0039] 3) Cell cryopreservation: Reheat the necessary reagents, take out the cells that need to be cryopreserved from the incubator, add sterile PBS to wash twice, then remove the PBS, add trypsin to digest the cells, and when it reaches a certain level, add 3-5mL of culture medium into the flask to stop the digestion, then use a pipette to pipette the cells, transfer them to a new centrifuge tube, and perform centrifugation. After the centrifugation is completed, discard the supernatant, add 0.5-1mL of cryopreservation solution into the centrifuge tube and mix evenly, and finally add the evenly mixed solution into the marked cryopreservation tube, seal it, and place it in a refrigerator at -80℃ for cryopreservation.
[0040] (2) CCK-8 experiment The cells in good condition were digested, then counted, and the concentration ratio was calculated. The corresponding volume of cell suspension and culture medium were then taken to adjust the cell concentration required for the experiment, and after thorough and uniform mixing, they were added to a 96-well plate. Various interventions were made on the cells according to the experimental requirements. After 48 hours, 10% CCK8 solution (the ratio of culture medium to CCK8 is 10:1) was added to each well, and the cells were placed in an incubator for further cultivation for 1-4 hours. The absorbance was then detected by a microplate reader, and the results were finally analyzed and statistically analyzed.
[0041] (3) Western blot experiment: The same as the animal experiment in Example 1. 1.2.Experimental Results (1) Detection of the effect of phenytoin sodium on hepatic stellate cell HSC proliferation by the CCK8 method and calculation of the IC50 value: The effect of phenytoin sodium on hepatic stellate cell HSC proliferation was detected by the CCK8 method, and the proliferation inhibition rate of different concentrations of phenytoin sodium on HSC cells was calculated. As a result, the IC50 value of phenytoin sodium on hepatic stellate cells was 234 μM (Figure 5).
[0042] (2) Detection of the effect of phenytoin sodium on the proliferation of TGF-β1-induced HSCs by CCK-8 method: The drug concentration was determined based on the IC50 value, and the concentration of PHT was set to 200μM to perform a cell-level correlation experiment. The effect of TGF-β1 on HSCs proliferation was detected by CCK8 method, and the results showed that compared with the normal group, the proliferation of HSCs was promoted after TGF-β1 stimulation, and the proliferation of HSCs promoted by TGF-β1 was inhibited after the addition of phenytoin sodium, and the results were statistically significant (p<0.05) (Figure 6).
[0043] (3) Detection of the expression of α-SMA, LC3, and P62 in cells of different experimental groups by Western blot: As shown in Figure 7, the expression of α-SMA in the TGF-β1 and phenytoin sodium co-stimulation group was obviously decreased compared with the TGF-β1 alone stimulation group, and the difference was statistically significant (p<0.05). In addition, as can be seen from the results of the Western blot experiment, the expression level of the autophagy-related protein LC3 was significantly decreased and the expression level of the autophagy substrate protein P62 was significantly increased under the co-stimulation of phenytoin sodium and TGF-β1 compared with the TGF-β1 alone stimulation group, and the difference was statistically significant (p<0.05). These results indicate that TGF-β1 can promote the occurrence of autophagy during the activation process of HSCs, whereas co-culture of phenytoinbata and TGF-β1 can suppress the occurrence of autophagy during the activation process of HSCs, which may affect the progression of liver fibrosis development by suppressing the activation of HSCs.
[0044] (4) Western blot demonstrated that the reversal of HSCs activation by phenytoin sodium was due to the inhibition of autophagy occurrence: As shown in Figure 8, after co-culture of HSCs with phenytoin sodium and TGF-β1, the expression of α-SMA and autophagy-related protein LC3 decreased, and the expression of P62 increased. After adding the autophagy agonist rapamycin, the expression of α-SMA and autophagy-related protein LC3 increased, and the expression of autophagy substrate protein P62 decreased in the rapamycin, phenytoin sodium and TGF-β1 group compared with the phenytoin sodium and TGF-β1 group, and the difference was statistically significant (p<0.05). After adding the autophagy agonist, the results were restored, indicating that phenytoin sodium indeed exerts an effect of affecting the activation of hepatic stellate cells by regulating the autophagy pathway, and further improving liver fibrosis.
[0045] The above-mentioned embodiments are merely illustrative of the preferred embodiments of the present invention, and are not intended to limit the scope of the present invention. Any modifications and improvements made by those skilled in the art to the technical means of the present invention without departing from the design concept of the present invention should be included within the scope of protection defined by the claims of the present invention.
Claims
1. 23. Use of a channel blocker in the manufacture of a medicament for the treatment and / or prevention of liver fibrosis.
2. 2. The use according to claim 1, characterized in that the channel blocker is a sodium channel blocker.
3. The use according to claim 2, characterized in that the sodium channel blocker comprises phenytoin sodium.
4. The use according to claim 1, characterized in that the liver fibrosis comprises carbon tetrachloride-induced liver fibrosis.
5. The use according to claim 1, characterized in that the medicament further comprises pharma- ceutically acceptable auxiliary materials.
6. The use according to claim 5, characterized in that the pharmaceutical formulation is any medically acceptable formulation.
7. The use according to claim 6, characterized in that the pharmaceutical dosage forms include powders, injections, capsules, tablets and oral liquids.
8. Use of phenytoin sodium in the manufacture of a medicine for inhibiting autophagy in liver tissue.
9. 23. Use of phenytoin sodium in the manufacture of a medicament for inhibiting hepatic stellate cell proliferation.
10. 23. Use of phenytoin sodium in the manufacture of a medicament for downregulating hepatocyte α-SMA.
Citation Information
Patent Citations
Substituted indanylidineacetylguanidines as Na+ / H+ exchange inhibitors, process for their preparation, their use as medicaments or diagnostic agents and medicaments containing them
EP0822182A1
Substituted sulfonimidamide, its production, its use as drugor diagnostic agent, and drug containing it
JP1997169723A
New kojic acid derivative and use as depigmentation agent
JP1998067781A
